DiaMedica Therapeutics Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| DMAC | LLY | |
|---|---|---|
| Market Cap | $370.47 million | $1.08 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | $-37,541,000 | $26.71 billion |
LLY leads on 2 of 2 size & scale factors.
Valuation
| DMAC | LLY | |
|---|---|---|
| P/E Ratio | — | 40.96 |
| Price / Book | 9.66 | 31.97 |
| Price / Sales | — | 13.59 |
DMAC leads on 1 of 1 valuation factors.
Profitability
| DMAC | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | -97.92% | 78.84% |
LLY leads on 1 of 1 profitability factors.
Risk & Sentiment
| DMAC | LLY | |
|---|---|---|
| Short Interest | 0.05% | 1.29% |
DMAC leads on 1 of 1 risk & sentiment factors.
Dig deeper: DMAC overview, DMAC financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.